Baba, Kenji http://orcid.org/0000-0003-3665-4092
Guo, Wenjia
Chen, Yirong
Nosaka, Tadashi
Kato, Tadafumi
Funding for this research was provided by:
Sumitomo Pharma Co., Ltd., Tokyo, Japan.
Article History
Received: 24 November 2021
Accepted: 7 June 2022
First Online: 18 June 2022
Declarations
:
: The 2019 NHWS surveys were cross-sectional surveys conducted in a total of 12 nations including Japan and the Japan survey was approved with exemption status upon review by Pearl Institutional Review Board (Indianapolis, IN, IRB Study Number: 19-KAN-196). All NHWS respondents provided informed consent prior to participating.
: Not applicable.
: Kenji Baba and Tadashi Nosaka are full-time employees of Sumitomo Pharma Co., Ltd., Tokyo, Japan. Wenjia Guo and Yirong Chen are employed at Cerner Enviza, Singapore. Tadafumi Kato reports personal fees from Kyowa Hakko Kirin, Eli Lilly, Otsuka, GlaxoSmithKline, Taisho Pharma, Taisho Pharmaceutical, Sumitomo Pharma, Meiji Seika Pharma, Pfizer, Mochida Pharmaceutical, Shionogi, Janssen Pharmaceutical, Janssen Asia Pacific, Yoshitomiyakuhin, Mitsubishi Tanabe Pharma, Astellas Pharma, Wako Pure Chemical Industries, Nippon Boehringer Ingelheim, MSD, Kyowa Pharmaceutical, Eisai and Takeda, and also reports a research grant from Takeda, Otsuka, Eisai, Sumitomo Pharma, Shionogi, Mitsubishi Tanabe Pharma, Teijin Pharma.